Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety of RG2077 in Patients With Multiple Sclerosis
This study has been completed.
Study NCT00076934.   Last updated on May 13, 2009.
Information provided by National Institute of Allergy and Infectious Diseases (NIAID)
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Multiple Sclerosis
Additional conditions recognized in this trial
Multiple Sclerosis, Relapsing-Remitting
Sclerosis
More general conditions related to this trial
Autoimmune Diseases
Autoimmune Diseases of the Nervous System
Demyelinating Autoimmune Diseases, CNS
Demyelinating Diseases
Immune System Diseases
Nervous System Diseases
Pathologic Processes
Interventions listed in this trial
RG2077 (CTLA4-IgG4m)
Sponsors listed in this trial
National Institute of Allergy and Infectious Diseases (NIAID)
Immune Tolerance Network


U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services